MedPath

Precigen

Precigen logo
🇺🇸United States
Ownership
Public
Established
1998-01-01
Employees
202
Market Cap
$330.8M
Website
http://www.precigen.com
Introduction

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Confirmatory Study of PRGN-2012 in Patients With RRP

Phase 3
Recruiting
Conditions
Recurrent Respiratory Papillomatosis
Papillomaviridae
Papillomavirus Infection
Interventions
First Posted Date
2024-08-05
Last Posted Date
2024-08-19
Lead Sponsor
Precigen, Inc
Target Recruit Count
42
Registration Number
NCT06538480
Locations
🇺🇸

National Institute of Health, Bethesda, Maryland, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer

Phase 2
Recruiting
Conditions
Cervical Cancer
HPV-Related Carcinoma
HPV-Related Malignancy
Recurrent Cervical Carcinoma
Metastatic Cervical Cancer
Interventions
First Posted Date
2023-12-05
Last Posted Date
2024-11-08
Lead Sponsor
Precigen, Inc
Target Recruit Count
46
Registration Number
NCT06157151
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

National Institute of Health, Bethesda, Maryland, United States

Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis

Phase 1
Active, not recruiting
Conditions
Papillomavirus Infections
Recurrent Respiratory Papillomatosis
Papillomaviridae
Interventions
First Posted Date
2021-01-26
Last Posted Date
2024-11-08
Lead Sponsor
Precigen, Inc
Target Recruit Count
38
Registration Number
NCT04724980
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Interventions
First Posted Date
2019-04-25
Last Posted Date
2024-11-08
Lead Sponsor
Precigen, Inc
Target Recruit Count
88
Registration Number
NCT03927261
Locations
🇺🇸

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1
Active, not recruiting
Conditions
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Refractory Fallopian Tube Carcinoma
Refractory Ovarian Carcinoma
Stage III Fallopian Tube Cancer AJCC V8
Stage III Ovarian Cancer AJCC V8
Interventions
Biological: PRGN-3005 UltraCAR-T cells
First Posted Date
2019-04-09
Last Posted Date
2024-11-08
Lead Sponsor
Precigen, Inc
Target Recruit Count
71
Registration Number
NCT03907527
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

National Institutes of Health (NIH), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath